EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis

Sei Muraoka iD, William D Brodie, Megan N Mattichak iD, Mikel Gurrea-Rubio iD, Yuzo Ikari iD, Caroline Foster, M Asif Amin, Neha Khanna, Hafsa Amin, Phillip L Campbell, Sirapa Vichaikul, Ellen N Model und 15 weitere

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.42973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Sei Muraoka und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, and Toho University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Fibrosis, CD13 Antigens, Scleroderma, Systemic, Skin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Systemic sclerosis (SSc) is an autoimmune multisystem disease with poorly understood pathogenesis and ineffective treatment options. Soluble CD13 (sCD13), generated by the cleavage of cell surface CD13 via matrix metalloproteinase 14 (MMP14), signals through the bradykinin receptor B1 (B1R) to elicit pro‐inflammatory, pro‐arthritic, and pro‐angiogenic responses. In this study, we explored the antifibrotic potential of targeting the sCD13‐B1R axis in SSc.

Methods

The expression of CD13, B1R, and MMP14 was examined in SSc skin and explanted dermal fibroblasts. The efficacy of B1R antagonists in the inhibition on fibrosis was determined in vitro and in vivo.

Results

Expression of the genes for CD13, B1R, and MMP14 was elevated in skin biopsies from patients with diffuse cutaneous (dc) SSc. Notably, single‐cell analysis of SSc skin biopsies revealed the highest BDKRB1 expression in COL8A1 ‐positive myofibroblasts, a population exclusively seen in SSc. Transforming growth factor beta (TGFβ) induced the expression of BDKRB1 and production of sCD13 by dcSSc skin fibroblasts. Treatment of dcSSc fibroblasts with sCD13 promoted fibrotic gene expression, signaling, cell proliferation, migration, and gel contraction. The pro‐fibrotic responses of sCD13 or TGFβ were prevented by a B1R antagonist. Mice lacking Cd13 or Bdkrb1 were resistant to bleomycin‐induced skin fibrosis and inflammation. Pharmacological B1R inhibition had a comparable antifibrotic effect.

Conclusion

These results are the first to demonstrate a key role for sCD13 in SSc skin fibrosis and suggest that targeting the sCD13‐B1R signaling axis is a promising novel therapeutic approach for SSc. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FibrosisCD13 AntigensScleroderma, SystemicSkinFibroblastsHumansAnimalsMiceMatrix Metalloproteinase 14Transforming Growth Factor betaBleomycin

Substanzen

CD13 AntigensMatrix Metalloproteinase 14Transforming Growth Factor betaBleomycin

Autor:innen und Institutionen

  • University of Michigan, Ann Arbor, and Toho University School of Medicine, Tokyo, Japan.
  • University of Michigan, Ann Arbor.
  • University of Michigan, Ann Arbor and Showa University School of Medicine, Tokyo, Japan.

ORCID-Profile: Sei Muraoka, Megan N Mattichak, Mikel Gurrea-Rubio, Yuzo Ikari, Jeffrey H Ruth, Lam C Tsoi, John Varga, Johann E Gudjonsson, Dinesh Khanna, Pei-Suen Tsou

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NIAMS NIH HHS
  • Edward T. and Ellen K. Dryer Early Career Professor of Rheumatology
  • University of Michigan
  • Beverley and Michael Townsley Fund for Scleroderma Biorepository
  • Japan Research Foundation for Clinical Pharmacology
  • National Scleroderma Foundation

Zitieren

APA

Muraoka, S., Brodie, W. D., Mattichak, M. N., Gurrea-Rubio, M., Ikari, Y., Foster, C., Amin, M. A., Khanna, N., Amin, H., Campbell, P. L., Vichaikul, S., Model, E. N., Omara, M. M., Petrovski, S., Kozicki, K., Amarista, C., Webber, A., Ali, M., Palisoc, P. J., …, & Tsou, P. S. (2025). Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42973

Vancouver

Muraoka S, Brodie WD, Mattichak MN, Gurrea-Rubio M, Ikari Y, Foster C, et al. Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis. Arthritis & Rheumatology. 2025. doi:10.1002/art.42973

BibTeX
@article{Muraoka2025,
  author = {Muraoka, Sei and Brodie, William D and Mattichak, Megan N and Gurrea-Rubio, Mikel and Ikari, Yuzo and Foster, Caroline and Amin, M Asif and Khanna, Neha and Amin, Hafsa and Campbell, Phillip L and Vichaikul, Sirapa and Model, Ellen N and Omara, Morgan M and Petrovski, Steven and Kozicki, Karly and Amarista, Camilia and Webber, Anna and Ali, Mustafa and Palisoc, Pamela J and Hervoso, Jonatan and Ruth, Jeffrey H and Tsoi, Lam C and Varga, John and Gudjonsson, Johann E and Khanna, Dinesh and Fox, David A and Tsou, Pei-Suen},
  title = {Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.42973}
}
Kostenlos starten →